DE60238330D1 - Immunologisch bedeutende herpes-simplex-virus-antigene und verfahren für ihre verwendung - Google Patents

Immunologisch bedeutende herpes-simplex-virus-antigene und verfahren für ihre verwendung

Info

Publication number
DE60238330D1
DE60238330D1 DE60238330T DE60238330T DE60238330D1 DE 60238330 D1 DE60238330 D1 DE 60238330D1 DE 60238330 T DE60238330 T DE 60238330T DE 60238330 T DE60238330 T DE 60238330T DE 60238330 D1 DE60238330 D1 DE 60238330D1
Authority
DE
Germany
Prior art keywords
hsv
amino acids
simplex virus
fragment
herpes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60238330T
Other languages
German (de)
English (en)
Inventor
David M Koelle
Nancy Ann Hosken
Christine M Posavad
Hongbo Chen
Patrick Mcgowan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Fred Hutchinson Cancer Center
Original Assignee
University of Washington
Corixa Corp
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Corixa Corp, Fred Hutchinson Cancer Center filed Critical University of Washington
Application granted granted Critical
Publication of DE60238330D1 publication Critical patent/DE60238330D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60238330T 2001-07-31 2002-07-31 Immunologisch bedeutende herpes-simplex-virus-antigene und verfahren für ihre verwendung Expired - Lifetime DE60238330D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30892301P 2001-07-31 2001-07-31
US30942801P 2001-08-01 2001-08-01
PCT/US2002/024306 WO2003011893A2 (en) 2001-07-31 2002-07-31 Immunologically significant herpes simplex virus antigens and methods for using same

Publications (1)

Publication Number Publication Date
DE60238330D1 true DE60238330D1 (de) 2010-12-30

Family

ID=26976523

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60238330T Expired - Lifetime DE60238330D1 (de) 2001-07-31 2002-07-31 Immunologisch bedeutende herpes-simplex-virus-antigene und verfahren für ihre verwendung

Country Status (8)

Country Link
US (2) US6814969B2 (enExample)
EP (2) EP2191845A1 (enExample)
JP (1) JP4519461B2 (enExample)
AT (1) ATE488249T1 (enExample)
AU (1) AU2002317604A1 (enExample)
CA (1) CA2454750C (enExample)
DE (1) DE60238330D1 (enExample)
WO (1) WO2003011893A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60324678D1 (de) 2002-07-18 2008-12-24 Univ Washington N t-lymphozyten und damit identifizierte hsv-antigene
US8541002B2 (en) 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
CA2605078C (en) * 2005-04-15 2013-01-08 Human Matrix Sciences, Llc Plant-derived elastin binding protein ligands and methods of using the same
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
US7628993B2 (en) 2006-07-20 2009-12-08 Vical Incorporated Compositions and methods for vaccinating against HSV-2
DE112008000888T5 (de) 2007-04-04 2011-05-19 Hugh Birchwood McTavish Nichtspezifische verzögerte Überempfindlichkeitsreaktion zur Behandlung von Herpes-Simplex-Virusinfektionen
ES2588705T3 (es) * 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US8460674B2 (en) * 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
EP2413950A4 (en) 2009-04-03 2013-05-01 Univ Washington ANTIGENIC HSV-2 PEPTIDE AND METHOD OF USE THEREOF
RU2585961C9 (ru) * 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
WO2012061637A2 (en) * 2010-11-03 2012-05-10 University Of Washington Hsv-1 epitopes and methods for using same
JP6055776B2 (ja) 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法
IN2014CN02581A (enExample) 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
JP6199878B2 (ja) 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
AU2016225025B2 (en) 2015-02-26 2020-07-16 Squarex, Llc Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection
JP2019512501A (ja) * 2016-03-14 2019-05-16 レッドバイオテック・アーゲーＲｅｄｂｉｏｔｅｃ Ａｇ Ｈｓｖを処置するための手段及び方法
EP3519427A4 (en) 2016-09-28 2020-03-11 Genocea Biosciences Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF HERPES
WO2019018796A1 (en) * 2017-07-21 2019-01-24 Fred Hutchinson Cancer Research Center VACCINE EPITOPES AGAINST HERPES SIMPLEX VIRUS RECOGNIZED SPECIFICALLY BY MEMORY T LYMPHOCYTES RESIDING IN FABRICS
CN112710849A (zh) * 2020-12-24 2021-04-27 首都医科大学附属北京友谊医院 一种鉴定抗EBV免疫活性的ELISpot试剂盒、制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA2088600C (en) 1990-08-02 1999-11-16 Rae L. Burke Herpes simplex virus vp16 vaccines
CA2090295A1 (en) 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
AU705563B2 (en) 1995-07-28 1999-05-27 Marie Curie Cancer Care Transport proteins and their uses
GB9615726D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Anti-viral agent 11
CA2270282A1 (en) 1996-11-04 1998-05-14 Smithkline Beecham Corporation Novel coding sequences from herpes simplex virus type-2
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
CA2291010A1 (en) * 1997-06-02 1998-12-10 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
CN1348463A (zh) 1998-08-07 2002-05-08 华盛顿大学 免疫学单纯疱疹病毒抗原及其使用方法
JP2003512305A (ja) * 1999-09-30 2003-04-02 ユニバーシティ オブ ワシントン 免疫学的に重要な単純疱疹ウイルス抗原
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6537555B2 (en) * 2000-06-29 2003-03-25 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection

Also Published As

Publication number Publication date
JP2004537308A (ja) 2004-12-16
ATE488249T1 (de) 2010-12-15
EP2191845A1 (en) 2010-06-02
EP1420821B8 (en) 2011-02-02
CA2454750C (en) 2012-09-18
CA2454750A1 (en) 2003-02-13
WO2003011893A2 (en) 2003-02-13
EP1420821A2 (en) 2004-05-26
US20030190324A1 (en) 2003-10-09
US6814969B2 (en) 2004-11-09
AU2002317604A1 (en) 2003-02-17
US7037509B2 (en) 2006-05-02
JP4519461B2 (ja) 2010-08-04
WO2003011893A3 (en) 2003-09-12
EP1420821A4 (en) 2006-08-30
US20040241182A1 (en) 2004-12-02
EP1420821B1 (en) 2010-11-17

Similar Documents

Publication Publication Date Title
EP1420821A4 (en) IMMUNOLOGICALLY IMPRESSIVE HERPES-SIMPLEX VIRUS ANTIGENS AND METHODS OF THEIR USE
EP2011510A3 (en) Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
MX9702714A (es) Produccion de peptidos en plantas como fusiones de proteinas con revestimiento viral.
ECSP064643A (es) Proteinas de fusion de glp-1
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
ES2077666T3 (es) Proteina de union a fibronectina y su preparacion.
CA2111645A1 (en) Fibrinogen fragment e peptides and antibodies thereto
GR3034349T3 (en) Neutralizing monoclonal antibodies to respiratory syncytial virus
DE69434413D1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
IL135688A0 (en) Human checkpoint kinase, hcds1, compositions and methods
PT1417222E (pt) Polipéptidos isolados baseados no epítopo neutralizante da proteína p17 de vih, úteis como vacinas, e anticorpos antip17 neutralizantes que reconhecem especificamente o referido polipéptido neutralizante
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
AU3850997A (en) Immunologically active proteins of borrelia burgdorferi, coded nuclein acids of such and their use in test kits and vaccines
PT635025E (pt) Processo para preparar proteinas modificadas
ATE314474T1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
WO1996002572A3 (fr) Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci
DE69840628D1 (de) Nicht-anaphylaktische allergenarten und ihre verwendung
AU2865801A (en) Therapeutic peptides
AU1444699A (en) Single-chain polypeptides comprising troponin i and troponin
ATE108802T1 (de) Polypeptidhemmer für virale replikation.
NO20011263D0 (no) Moraxella Catarrhalis BASBO34-polypeptider og anvendelser derav
GB2357507A (en) Peptide fragments of cholera toxin B or enterotoxin B as vaccine adjuvants
ATE234358T1 (de) Peptide des pferdearteritisvirus, antikörper und ihre verwendung in einem diagnostischen test
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid
WO2003099995A3 (en) Murine ortholog of the human disrupted-in-schizophrenia 1 gene

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: FRED HUTCHINSON CANCER RESEARCH CENTER, SEATTL, US

Owner name: UNIVERSITY OF WASHINGTON, SEATTLE, WASH., US